Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2398852 + GSK2315698 in Cardiac Amyloidosis
NCT03044353Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2017
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of dezamizumab in cardiac amyloidosis, sponsored by GSK. Started Jul 2017; status: terminated.
02
Drugs
dezamizumab
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT03044353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044353.